
Andrew D Dick

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2750263/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2016, 10, 239-254.	0.6	577
2	Adalimumab in Patients with Active Noninfectious Uveitis. New England Journal of Medicine, 2016, 375, 932-943.	13.9	470
3	Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet, The, 2016, 388, 1183-1192.	6.3	387
4	Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis. New England Journal of Medicine, 2017, 376, 1637-1646.	13.9	315
5	Secukinumab in the Treatment of Noninfectious Uveitis: Results of Three Randomized, Controlled Clinical Trials. Ophthalmology, 2013, 120, 777-787.	2.5	287
6	Predicting Endothelial Cell Loss and Long-Term Corneal Graft Survival. , 2003, 44, 3326.		234
7	A systems biology approach towards understanding and treating non-neovascular age-related macular degeneration. Nature Communications, 2019, 10, 3347.	5.8	192
8	Constitutive Retinal CD200 Expression Regulates Resident Microglia and Activation State of Inflammatory Cells during Experimental Autoimmune Uveoretinitis. American Journal of Pathology, 2002, 161, 1669-1677.	1.9	190
9	Guidance on Noncorticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis. Ophthalmology, 2018, 125, 757-773.	2.5	178
10	The role of tumour necrosis factor (TNF-α) in experimental autoimmune uveoretinitis (EAU). Progress in Retinal and Eye Research, 2004, 23, 617-637.	7.3	175
11	Dendritic cell physiology and function in the eye. Immunological Reviews, 2010, 234, 282-304.	2.8	172
12	Electric Field–directed Cell Motility Involves Up-regulated Expression and Asymmetric Redistribution of the Epidermal Growth Factor Receptors and Is Enhanced by Fibronectin and Laminin. Molecular Biology of the Cell, 1999, 10, 1259-1276.	0.9	154
13	Cyclosporine vs Tacrolimus Therapy for Posterior and Intermediate Uveitis. JAMA Ophthalmology, 2005, 123, 634.	2.6	149
14	Biologics in the treatment of uveitis. Current Opinion in Ophthalmology, 2007, 18, 481-486.	1.3	145
15	Analysis of retinal cellular infiltrate in experimental autoimmune uveoretinitis reveals multiple regulatory cell populations. Journal of Autoimmunity, 2008, 31, 354-361.	3.0	141
16	Risk of Ocular Complications in Patients with Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis. Ophthalmology, 2016, 123, 655-662.	2.5	141
17	Turnover of resident retinal microglia in the normal adult mouse. Glia, 2007, 55, 1189-1198.	2.5	139
18	IL-10 regulation of macrophage VEGF production is dependent on macrophage polarisation and hypoxia. Immunobiology, 2010, 215, 796-803.	0.8	139

#	Article	IF	CITATIONS
19	Safety and Efficacy of Adalimumab in Patients with Noninfectious Uveitis in an Ongoing Open-Label Study: VISUAL III. Ophthalmology, 2018, 125, 1075-1087.	2.5	134
20	Rescue therapy with mycophenolate mofetil in refractory uveitis. Lancet, The, 1998, 352, 35-36.	6.3	131
21	Inhibition of tumor necrosis factor activity minimizes target organ damage in experimental autoimmune uveoretinitis despite quantitatively normal activated T cell traffic to the retina. European Journal of Immunology, 1996, 26, 1018-1025.	1.6	129
22	Autoimmune and autoinflammatory mechanisms in uveitis. Seminars in Immunopathology, 2014, 36, 581-594.	2.8	120
23	Monoclonal Antibody-Mediated CD200 Receptor Signaling Suppresses Macrophage Activation and Tissue Damage in Experimental Autoimmune Uveoretinitis. American Journal of Pathology, 2007, 171, 580-588.	1.9	118
24	Long-term Efficacy and Tolerance of Tacrolimus for the Treatment of Uveitis. Ophthalmology, 2007, 114, 1000-1006.e4.	2.5	116
25	Signalling of DNA damage and cytokines across cell barriers exposed to nanoparticles depends on barrier thickness. Nature Nanotechnology, 2011, 6, 824-833.	15.6	114
26	Autoimmunity, Autoinflammation, and Infection in Uveitis. American Journal of Ophthalmology, 2018, 189, 77-85.	1.7	111
27	The Standardization of Uveitis Nomenclature (SUN) Project. Methods of Information in Medicine, 2013, 52, 259-265.	0.7	110
28	Multicenter Study of Intravitreal Dexamethasone Implant in Noninfectious Uveitis: Indications, Outcomes, and Reinjection Frequency. American Journal of Ophthalmology, 2014, 158, 1136-1145.e5.	1.7	109
29	Objective Measurement of Vitreous Inflammation Using Optical Coherence Tomography. Ophthalmology, 2014, 121, 1706-1714.	2.5	104
30	Treatment Strategies in Primary Vitreoretinal Lymphoma. JAMA Ophthalmology, 2015, 133, 191.	1.4	104
31	Neutralizing TNF-alpha Activity Modulates T-cell Phenotype and Function in Experimental Autoimmune Uveoretinitis. Journal of Autoimmunity, 1998, 11, 255-264.	3.0	103
32	Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses. Science Translational Medicine, 2021, 13, .	5.8	99
33	Homeostatic regulation of T cell trafficking by a B cell–derived peptide is impaired in autoimmune and chronic inflammatory disease. Nature Medicine, 2015, 21, 467-475.	15.2	94
34	The dynamics of leukocyte infiltration in experimental autoimmune uveoretinitis. Progress in Retinal and Eye Research, 2008, 27, 527-535.	7.3	92
35	A randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis (SYCAMORE Trial). Trials, 2014, 15, 14.	0.7	89
36	Control of myeloid activity during retinal inflammation. Journal of Leukocyte Biology, 2003, 74, 161-166.	1.5	86

#	Article	IF	CITATIONS
37	Uveitis associated with juvenile idiopathic arthritis. Nature Reviews Rheumatology, 2015, 11, 338-348.	3.5	86
38	Interplay between innate and adaptive immunity in the development of non-infectious uveitis. Progress in Retinal and Eye Research, 2012, 31, 182-194.	7.3	85
39	Tacrolimus (FK506) in failed cyclosporin A therapy in endogenous posterior uveitis. Ocular Immunology and Inflammation, 1998, 6, 101-109.	1.0	84
40	Nitric Oxide Mediates Apoptosis Through Formation of Peroxynitrite and Fas/Fas-Ligand Interactions in Experimental Autoimmune Uveitis. American Journal of Pathology, 2002, 160, 905-916.	1.9	83
41	The Role of the Immune Response in Age-Related Macular Degeneration. International Journal of Inflammation, 2013, 2013, 1-10.	0.9	82
42	Myeloid Cells Expressing VEGF and Arginase-1 Following Uptake of Damaged Retinal Pigment Epithelium Suggests Potential Mechanism That Drives the Onset of Choroidal Angiogenesis in Mice. PLoS ONE, 2013, 8, e72935.	1.1	79
43	Neutralizing Tumor Necrosis Factor-α Activity Suppresses Activation of Infiltrating Macrophages in Experimental Autoimmune Uveoretinitis. , 2003, 44, 3034.		78
44	Retinal microenvironment controls resident and infiltrating macrophage function during uveoretinitis. Investigative Ophthalmology and Visual Science, 2002, 43, 2250-7.	3.3	76
45	Generation of Activated Sialoadhesin-Positive Microglia during Retinal Degeneration. , 2003, 44, 2229.		74
46	Systemic and local anti-C5 therapy reduces the disease severity in experimental autoimmune uveoretinitis. Clinical and Experimental Immunology, 2010, 159, 303-314.	1.1	73
47	Changes in the balance of the tissue inhibitor of matrix metalloproteinases (TIMPs)-1 and -3 may promote keratocyte apoptosis in keratoconus. Experimental Eye Research, 2007, 84, 1125-1134.	1.2	72
48	Behçet Disease-associated Uveitis Successfully Treated with Golimumab. Ocular Immunology and Inflammation, 2013, 21, 160-162.	1.0	71
49	Mycophenolate Mofetil for the Treatment of Uveitis. American Journal of Ophthalmology, 2008, 146, 752-760.e3.	1.7	69
50	Glucocorticoid-resistant Th17 cells are selectively attenuated by cyclosporine A. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 4080-4085.	3.3	68
51	Combined immunosuppression and radiotherapy in thyroid eye disease (CIRTED): a multicentre, 2â€^×â€^2 factorial, double-blind, randomised controlled trial. Lancet Diabetes and Endocrinology,the, 2018, 6, 299-309.	5.5	68
52	Topical Antiangiogenic SRPK1 Inhibitors Reduce Choroidal Neovascularization in Rodent Models of Exudative AMD. , 2013, 54, 6052.		67
53	Immune Responses in Age-Related Macular Degeneration and a Possible Long-term Therapeutic Strategy for Prevention. American Journal of Ophthalmology, 2014, 158, 5-11.e2.	1.7	67
54	Direct ex vivo flow cytometric analysis of human microglial cell CD4 expression. Aids, 1997, 11, 1699-1708.	1.0	64

#	Article	IF	CITATIONS
55	Neutralizing Tumor Necrosis Factor Activity Leads to Remission in PatientsWith Refractory Noninfectious Posterior Uveitis. JAMA Ophthalmology, 2004, 122, 845.	2.6	64
56	Clinical Review: Anti-TNFα Therapies in Uveitis: Perspective on 5 Years of Clinical Experience. Ocular Immunology and Inflammation, 2009, 17, 403-414.	1.0	64
57	Comparison of Associations with Different Macular Inner Retinal Thickness Parameters in a Large Cohort. Ophthalmology, 2020, 127, 62-71.	2.5	64
58	Inflammatory choroidal neovascular membrane in posterior uveitis-pathogenesis and treatment. Indian Journal of Ophthalmology, 2010, 58, 3.	0.5	64
59	The Clinical Time-Course of Experimental Autoimmune Uveoretinitis Using Topical Endoscopic Fundal Imaging with Histologic and Cellular Infiltrate Correlation. , 2008, 49, 5458.		63
60	Mechanisms of TNFα regulation in uveitis: Focus on RNA-binding proteins. Progress in Retinal and Eye Research, 2010, 29, 610-621.	7.3	62
61	Impairing autophagy in retinal pigment epithelium leads to inflammasome activation and enhanced macrophage-mediated angiogenesis. Scientific Reports, 2016, 6, 20639.	1.6	62
62	Blau Syndrome–Associated Uveitis: Preliminary Results From an International Prospective Interventional Case Series. American Journal of Ophthalmology, 2018, 187, 158-166.	1.7	62
63	Tocilizumab in patients with anti-TNF refractory juvenile idiopathic arthritis-associated uveitis (APTITUDE): a multicentre, single-arm, phase 2 trial. Lancet Rheumatology, The, 2020, 2, e135-e141.	2.2	62
64	Cellular senescence in the aging retina and developments of senotherapies for age-related macular degeneration. Journal of Neuroinflammation, 2021, 18, 32.	3.1	62
65	Minocycline delays photoreceptor death in the rds mouse through a microglia-independent mechanism. Experimental Eye Research, 2004, 78, 1077-1084.	1.2	61
66	Switching biologic agents for uveitis. Eye, 2009, 23, 1868-1870.	1.1	61
67	Effect of Adalimumab on Visual Functioning in Patients With Noninfectious Intermediate Uveitis, Posterior Uveitis, and Panuveitis in the VISUAL-1 and VISUAL-2 Trials. JAMA Ophthalmology, 2017, 135, 511.	1.4	61
68	Current concepts and future directions in the pathogenesis and treatment of non-infectious intraocular inflammation. Eye, 2012, 26, 17-28.	1.1	60
69	The Relationship Between Ambient Atmospheric Fine Particulate Matter (PM _{2.5}) and Glaucoma in a Large Community Cohort. , 2019, 60, 4915.		60
70	Anti-TNFα Therapy Modulates the Phenotype of Peripheral Blood CD4+T Cells in Patients with Posterior Segment Intraocular Inflammation. , 2004, 45, 170.		59
71	In Vivo Laser-Tissue Interactions and Healing Responses From 20- vs 100-Millisecond Pulse Pascal Photocoagulation Burns. JAMA Ophthalmology, 2010, 128, 448.	2.6	59
72	Direct and indirect resource use, healthcare costs and work force absence in patients with nonâ€infectious intermediate, posterior or panuveitis. Acta Ophthalmologica, 2016, 94, e331-9.	0.6	58

#	Article	IF	CITATIONS
73	Outcomes of non-infectious Paediatric uveitis in the era of biologic therapy. Pediatric Rheumatology, 2018, 16, 51.	0.9	58
74	Patterned growth of neuronal cells on modified diamond-like carbon substrates. Biomaterials, 2008, 29, 2573-2580.	5.7	57
75	Application of OCT-angiography to characterise the evolution of chorioretinal lesions in acute posterior multifocal placoid pigment epitheliopathy. Eye, 2017, 31, 1399-1408.	1.1	56
76	Distribution of OX2 antigen and OX2 receptor within retina. Investigative Ophthalmology and Visual Science, 2001, 42, 170-6.	3.3	56
77	Interobserver Agreement Among Uveitis Experts on Uveitic Diagnoses: The Standardization of Uveitis Nomenclature Experience. American Journal of Ophthalmology, 2018, 186, 19-24.	1.7	55
78	Complement factor H binding of monomeric C-reactive protein downregulates proinflammatory activity and is impaired with at risk polymorphic CFH variants. Scientific Reports, 2016, 6, 22889.	1.6	54
79	A Perspective of AMD Through the Eyes of Immunology. , 2018, 59, AMD83.		52
80	Gene Therapy for Glaucoma by Ciliary Body Aquaporin 1 Disruption Using CRISPR-Cas9. Molecular Therapy, 2020, 28, 820-829.	3.7	52
81	Cytokine Gene Polymorphism in Sympathetic Ophthalmia. , 2005, 46, 4245.		50
82	Local Administration of an Adeno-associated Viral Vector Expressing IL-10 Reduces Monocyte Infiltration and Subsequent Photoreceptor Damage during Experimental Autoimmune Uveitis. Molecular Therapy, 2005, 12, 369-373.	3.7	50
83	Use of infliximab in juvenile onset rheumatological disease-associated refractory uveitis: efficacy in joint and ocular disease. Annals of the Rheumatic Diseases, 2007, 66, 840-841.	0.5	49
84	Persistent Inflammation Subverts Thrombospondin-1–Induced Regulation of Retinal Angiogenesis and Is Driven by CCR2 Ligation. American Journal of Pathology, 2012, 180, 235-245.	1.9	49
85	A Selective Role for the TNF p55 Receptor in Autocrine Signaling following IFN-Î ³ Stimulation in Experimental Autoimmune Uveoretinitis. Journal of Immunology, 2005, 175, 6286-6293.	0.4	48
86	Heterogeneity of primary outcome measures used in clinical trials of treatments for intermediate, posterior, and panuveitis. Orphanet Journal of Rare Diseases, 2015, 10, 97.	1.2	48
87	Cataract surgery in uveitis: a multicentre database study. British Journal of Ophthalmology, 2017, 101, 1132-1137.	2.1	48
88	Immune Mechanisms of Uveitis: Insights Into Disease Pathogenesis and Treatment. International Ophthalmology Clinics, 2000, 40, 1-18.	0.3	47
89	Interleukinâ€33 regulates tissue remodelling and inhibits angiogenesis in the eye. Journal of Pathology, 2017, 241, 45-56.	2.1	47
90	TNFR1-Dependent Regulation of Myeloid Cell Function in Experimental Autoimmune Uveoretinitis. Journal of Immunology, 2009, 183, 2321-2329.	0.4	46

#	Article	IF	CITATIONS
91	Local therapies for inflammatory eye disease in translation: past, present and future. BMC Ophthalmology, 2013, 13, 39.	0.6	45
92	Assessment and In Vivo Scoring of Murine Experimental Autoimmune Uveoretinitis Using Optical Coherence Tomography. PLoS ONE, 2013, 8, e63002.	1.1	45
93	Blocking CD200-CD200 receptor axis augments NOS-2 expression and aggravates experimental autoimmune uveoretinitis in Lewis rats. Ocular Immunology and Inflammation, 2004, 12, 115-125.	1.0	43
94	Punctate Inner Choroidopathy and Multifocal Choroiditis with Panuveitis Share Haplotypic Associations with <i>IL10</i> and <i>TNF</i> Loci. , 2011, 52, 3573.		43
95	CD200 maintains microglial potential to migrate in adult human retinal explant model. Current Eye Research, 2004, 28, 427-436.	0.7	42
96	Therapeutic Dosing of Fingolimod (FTY720) Prevents Cell Infiltration, Rapidly Suppresses Ocular Inflammation, and Maintains the Blood-Ocular Barrier. American Journal of Pathology, 2012, 180, 672-681.	1.9	42
97	C-Reactive Protein as a Therapeutic Target in Age-Related Macular Degeneration. Frontiers in Immunology, 2018, 9, 808.	2.2	42
98	Cytokine Polymorphism in Noninfectious Uveitis. , 2010, 51, 4133.		41
99	SIRT1 activation protects against autoimmune T cell-driven retinal disease in mice via inhibition of IL-2/Stat5 signaling. Journal of Autoimmunity, 2013, 42, 117-129.	3.0	41
100	Multimodal analysis of ocular inflammation using endotoxin-induced uveitis. DMM Disease Models and Mechanisms, 2016, 9, 473-81.	1.2	41
101	SRPK1 Inhibition Modulates VEGF Splicing to Reduce Pathological Neovascularization in a Rat Model of Retinopathy of Prematurity. , 2013, 54, 5797.		39
102	Use of adalimumab in refractory non-infectious childhood chronic uveitis: efficacy in ocular diseasea case cohort interventional study. Rheumatology, 2012, 51, 2199-2203.	0.9	38
103	Current and future treatments for Behçet's uveitis: road to remission. International Ophthalmology, 2014, 34, 365-381.	0.6	38
104	Managing juvenile idiopathic arthritis–associated uveitis. Survey of Ophthalmology, 2016, 61, 197-210.	1.7	38
105	Enhanced Tolerance to Autoimmune Uveitis in CD200-Deficient Mice Correlates with a Pronounced Th2 Switch in Response to Antigen Challenge. Journal of Immunology, 2005, 174, 143-154.	0.4	37
106	Differential patterning of neuronal, glial and neural progenitor cells on phosphorus-doped and UV irradiated diamond-like carbon. Biomaterials, 2010, 31, 207-215.	5.7	37
107	Areas of agreement in the management of childhood non-infectious chronic anterior uveitis in the UK. British Journal of Ophthalmology, 2020, 104, 11-16.	2.1	37
108	Validity of using vision-related quality of life as a treatment end point in intermediate and posterior uveitis. British Journal of Ophthalmology, 2007, 91, 154-156.	2.1	36

#	Article	IF	CITATIONS
109	Microglia derived IL-6 suppresses neurosphere generation from adult human retinal cell suspensions. Experimental Eye Research, 2009, 89, 757-766.	1.2	35
110	Spatially controlling neuronal adhesion on CVD diamond. Diamond and Related Materials, 2012, 23, 100-104.	1.8	35
111	Adalimumab in Juvenile Idiopathic Arthritis–Associated Uveitis: 5-Year Follow-up of the Bristol Participants of the SYCAMORE Trial. American Journal of Ophthalmology, 2019, 207, 170-174.	1.7	35
112	Ambient Air Pollution Associations with Retinal Morphology in the UK Biobank. , 2020, 61, 32.		35
113	CD4+CD25int T Cells in Inflammatory Diseases Refractory to Treatment with Glucocorticoids. Journal of Immunology, 2007, 179, 7941-7948.	0.4	34
114	The use of rituximab in refractory mucous membrane pemphigoid with severe ocular involvement. British Journal of Ophthalmology, 2009, 93, 421-422.	2.1	34
115	Long-term efficacy and tolerability of TNFα inhibitors in the treatment of non-infectious ocular inflammation: an 8-year prospective surveillance study. British Journal of Ophthalmology, 2021, 105, 1256-1262.	2.1	34
116	Fingolimod (FTY720) as an Acute Rescue Therapy for Intraocular Inflammatory Disease. JAMA Ophthalmology, 2008, 126, 1390-1395.	2.6	33
117	Tissue-Resident Exhausted Effector Memory CD8+ T Cells Accumulate in the Retina during Chronic Experimental Autoimmune Uveoretinitis. Journal of Immunology, 2014, 192, 4541-4550.	0.4	33
118	IL-4 Regulates Specific Arg-1+ Macrophage sFlt-1–Mediated Inhibition of Angiogenesis. American Journal of Pathology, 2015, 185, 2324-2335.	1.9	33
119	Annexin-A1 restricts Th17 cells and attenuates the severity of autoimmune disease. Journal of Autoimmunity, 2015, 58, 1-11.	3.0	32
120	KINETICS OF LEUKOCYTE AND MYELOID CELL TRAFFIC IN THE MURINE CORNEAL ALLOGRAFT RESPONSE1. Transplantation, 2001, 72, 1292-1298.	0.5	32
121	Steroid Refractory CD4 ⁺ T Cells in Patients with Sight-Threatening Uveitis. , 2009, 50, 4273.		31
122	Environmental conditioning in the control of macrophage thrombospondin-1 production. Scientific Reports, 2012, 2, 512.	1.6	31
123	CD200R signaling inhibits pro-angiogenic gene expression by macrophages and suppresses choroidal neovascularization. Scientific Reports, 2013, 3, 3072.	1.6	31
124	Evaluation of Objective Vitritis Grading Method Using Optical Coherence Tomography: Influence of Phakic Status and Previous Vitrectomy. American Journal of Ophthalmology, 2016, 161, 172-180.e4.	1.7	31
125	Reduced Macular Vessel Density and Capillary Perfusion in Glaucoma Detected Using OCT Angiography. Current Eye Research, 2019, 44, 533-540.	0.7	31
126	Retinal Antigen Specific Lymphocytes, Tcr-Gamma Delta T Cells and Cd5+B Cells Cultured from the Vitreous in Acute Sympathetic Ophthalmitis. Autoimmunity, 1993, 15, 257-266.	1.2	30

#	Article	IF	CITATIONS
127	Modelling Macular Edema: The Effect of IL-6 and IL-6R Blockade on Human Blood–Retinal Barrier Integrity In Vitro. Translational Vision Science and Technology, 2019, 8, 32.	1.1	30
128	CD133+adult human retinal cells remain undifferentiated in Leukaemia Inhibitory Factor (LIF). BMC Ophthalmology, 2009, 9, 1.	0.6	29
129	Doyne lecture 2016: intraocular health and the many faces of inflammation. Eye, 2017, 31, 87-96.	1.1	29
130	Associations with Corneal Hysteresis in a Population Cohort. Ophthalmology, 2019, 126, 1500-1510.	2.5	29
131	A Randomized Trial of Tacrolimus versus Tacrolimus and Prednisone for the Maintenance of Disease Remission in Noninfectious Uveitis. Ophthalmology, 2012, 119, 1223-1230.	2.5	28
132	Inflammatory eye disease: Pre-treatment assessment of patients prior to commencing immunosuppressive and biologic therapy: Recommendations from an expert committee. Autoimmunity Reviews, 2017, 16, 213-222.	2.5	28
133	Nonsteroidal drugs for the treatment of noninfectious posterior and intermediate uveitis. Current Opinion in Ophthalmology, 2007, 18, 212-219.	1.3	27
134	Cancer-associated retinopathy presenting as retinal vasculitis with a negative ERG suggestive of on-bipolar cell pathway dysfunction. Documenta Ophthalmologica, 2011, 123, 59-63.	1.0	27
135	Plasma Exchange and Rituximab in the Management of Acute Occlusive Retinal Vasculopathy Secondary to Systemic Lupus Erythematosus Ocular Immunology and Inflammation, 2011, 19, 379-381.	1.0	26
136	Cross sectional, qualitative thematic analysis of patient perspectives of disease impact in juvenile idiopathic arthritis-associated uveitis. Pediatric Rheumatology, 2017, 15, 58.	0.9	26
137	The Eyes Have it. Arthritis and Rheumatology, 2018, 70, 1533-1543.	2.9	26
138	A review and update on the ophthalmic implications of Susac syndrome. Survey of Ophthalmology, 2019, 64, 477-485.	1.7	26
139	Protocol for the combined immunosuppression & radiotherapy in thyroid eye disease (CIRTED) trial: A multi-centre, double-masked, factorial randomised controlled trial. Trials, 2008, 9, 6.	0.7	25
140	Non-Infectious Pediatric Uveitis. Paediatric Drugs, 2009, 11, 229-241.	1.3	25
141	Tumour necrosis factor-mediated macrophage activation in the target organ is critical for clinical manifestation of uveitis. Clinical and Experimental Immunology, 2012, 168, 165-177.	1.1	25
142	Systemic therapies for inflammatory eye disease: Past, Present and Future. BMC Ophthalmology, 2013, 13, 18.	0.6	25
143	A phase II trial protocol of Tocilizumab in anti-TNF refractory patients with JIA-associated uveitis (the) Tj ETQq1 1	0.784314 0.6	rgBT /Over
144	Long-Term Safety and Efficacy of Adalimumab in Patients with Noninfectious Intermediate Uveitis,		95

Posterior Uveitis, or Panuveitis. Ophthalmology, 2021, 128, 899-909.

2.5 25

#	Article	IF	CITATIONS
145	Epidemiology of Scleritis in the United Kingdom From 1997 to 2018: Populationâ€Based Analysis of 11 Million Patients and Association Between Scleritis and Infectious and Immuneâ€Mediated Inflammatory Disease. Arthritis and Rheumatology, 2021, 73, 1267-1276.	2.9	25
146	Recent developments in the pharmacological treatment and prevention of corneal graft rejection. Expert Opinion on Investigational Drugs, 2003, 12, 29-37.	1.9	24
147	The effect of postmortem time, donor age and sex on the generation of neurospheres from adult human retina. British Journal of Ophthalmology, 2007, 91, 1216-1218.	2.1	24
148	Treat early and embrace the evidence in favour of anti-TNF-Â therapy for Behcet's uveitis. British Journal of Ophthalmology, 2010, 94, 269-270.	2.1	23
149	Optic nerve and retinal features in uveitis associated with juvenile systemic granulomatous disease (<scp>B</scp> lau syndrome). Acta Ophthalmologica, 2015, 93, 253-257.	0.6	23
150	Patient-reported wellbeing and clinical disease measures over time captured by multivariate trajectories of disease activity in individuals with juvenile idiopathic arthritis in the UK: a multicentre prospective longitudinal study. Lancet Rheumatology, The, 2021, 3, e111-e121.	2.2	23
151	Emerging therapies and their delivery for treating ageâ€related macular degeneration. British Journal of Pharmacology, 2022, 179, 1908-1937.	2.7	23
152	Influence of microglia on retinal progenitor cell turnover and cell replacement. Eye, 2009, 23, 1939-1945.	1.1	22
153	Anatomy of the eye and orbit. , 2016, , 1-102.e2.		22
154	Fragile Xâ€related protein FXR1 controls postâ€transcriptional suppression of lipopolysaccharideâ€induced tumour necrosis factorâ€i£ production by transforming growth factorâ€i²1. FEBS Journal, 2010, 277, 2754-2765.	2.2	21
155	TLR9 Agonist Regulates Angiogenesis and Inhibits Corneal Neovascularization. American Journal of Pathology, 2014, 184, 1900-1910.	1.9	21
156	Serum Vascular Endothelial Growth Factor Levels in the IVAN Trial; Relationships with Drug, Dosing, and Systemic Serious Adverse Events. Ophthalmology Retina, 2018, 2, 118-127.	1.2	21
157	Differences in leukocyte phenotype and interferon-Î ³ expression in stroma and endothelium during corneal graft rejection. Experimental Eye Research, 2006, 83, 339-347.	1.2	20
158	An anti-TNF-Î \pm antibody mimetic to treat ocular inflammation. Scientific Reports, 2016, 6, 36905.	1.6	20
159	Efficacy and safety of intravitreal antiâ€ŧumour necrosis factor drugs in adults with nonâ€infectious uveitis – a systematic review. Acta Ophthalmologica, 2018, 96, e665-e675.	0.6	20
160	Trial protocol: a multicentre randomised trial of first-line treatment pathways for newly diagnosed immune thrombocytopenia: standard steroid treatment versus combined steroid and mycophenolate. The FLIGHT trial. BMJ Open, 2018, 8, e024427.	0.8	20
161	Total dose and frequency of administration critically affect success of nasal mucosal tolerance induction. British Journal of Ophthalmology, 2001, 85, 739-744.	2.1	18
162	New insights into the genetic component of non-infectious uveitis through an Immunochip strategy. Journal of Medical Genetics, 2017, 54, 38-46.	1.5	18

#	Article	IF	CITATIONS
163	Cost-Effectiveness Analysis of Adalimumab for the Treatment of Uveitis Associated with Juvenile Idiopathic Arthritis. Ophthalmology, 2019, 126, 415-424.	2.5	18
164	Inflammation in Viral Vector-Mediated Ocular Gene Therapy: A Review and Report From a Workshop Hosted by the Foundation Fighting Blindness, 9/2020. Translational Vision Science and Technology, 2021, 10, 3.	1.1	18
165	Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCT. Health Technology Assessment, 2019, 23, 1-140.	1.3	18
166	Reduced mortality compared with national averages following phacoemulsification cataract surgery: a retrospective observational study. British Journal of Ophthalmology, 2009, 93, 290-295.	2.1	17
167	TNFα Regulates SIRT1 Cleavage during Ocular Autoimmune Disease. American Journal of Pathology, 2015, 185, 1324-1333.	1.9	17
168	Adalimumab in Active and Inactive, Non-Infectious Uveitis: Global Results from the VISUAL I and VISUAL II II Trials. Ocular Immunology and Inflammation, 2019, 27, 40-50.	1.0	17
169	The B Subunit ofEscherichia coliHeat-Labile Enterotoxin Inhibits Th1 but Not Th17 Cell Responses in Established Experimental Autoimmune Uveoretinitis. , 2008, 49, 4008.		16
170	Murine respiratory tract dendritic cells: isolation, phenotyping and functional studies. Journal of Immunological Methods, 2004, 287, 67-77.	0.6	15
171	Glucocorticoids and the emerging importance of T cell subsets in steroid refractory diseases. Immunopharmacology and Immunotoxicology, 2009, 31, 1-12.	1.1	15
172	TNFR1 signalling is a critical checkpoint for developing macrophages that control of Tâ \in ell proliferation. Immunology, 2010, 131, 340-349.	2.0	15
173	Distinguishing between the innate immune response due to ocular inflammation and infection in a child with juvenile systemic granulomatous disease treated with anti-TNF-Â monoclonal antibodies. Rheumatology, 2011, 50, 990-992.	0.9	15
174	The Safety and Efficacy of Noncorticosteroid Triple Immunosuppressive Therapy in the Treatment of Refractory Chronic Noninfectious Uveitis in Childhood. Journal of Rheumatology, 2014, 41, 136-139.	1.0	15
175	Personal protective equipment (PPE) for vitreoretinal surgery during COVID-19. Eye, 2020, 34, 1196-1199.	1.1	15
176	Juvenile Idiopathic Arthritis Associated Uveitis. Children, 2021, 8, 646.	0.6	15
177	Cataract Surgery in Pediatric Uveitis. Journal of Pediatric Ophthalmology and Strabismus, 2008, 45, 270-278.	0.3	15
178	What determines the site of inflammation in uveitis and chorioretinitis?. Eye, 1997, 11, 162-166.	1.1	14
179	Adalimumab for Uveitis in Juvenile Idiopathic Arthritis. New England Journal of Medicine, 2017, 377, 789-790.	13.9	14
180	Discontinuing adalimumab in patients with controlled juvenile idiopathic arthritis-associated uveitis (ADJUST—Adalimumab in Juvenile Idiopathic Arthritis-associated Uveitis Stopping Trial): study protocol for a randomised controlled trial. Trials, 2020, 21, 887.	0.7	14

#	Article	IF	CITATIONS
181	Single Eye mRNA-Seq Reveals Normalisation of the Retinal Microglial Transcriptome Following Acute Inflammation. Frontiers in Immunology, 2019, 10, 3033.	2.2	14
182	Tumor necrosis factor polymorphisms associated with tumor necrosis factor production influence the risk of idiopathic intermediate uveitis. Molecular Vision, 2013, 19, 184-95.	1.1	14
183	Phenotypic analysis of retinal leukocyte infiltration during combined cyclosporin a and nasal antigen administration of retinal antigens: delay and inhibition of macrophage and granulocyte infiltration. Ocular Immunology and Inflammation, 1997, 5, 129-140.	1.0	13
184	Intranasal Administration of Retinal Antigens Induces Transient T cell Activation and Apoptosis within Drainage Lymph Nodes but not Spleen. Journal of Autoimmunity, 1999, 12, 145-155.	3.0	13
185	Recovery From Macular Phototoxicity After Corneal Triple Procedure. Cornea, 2007, 26, 102-104.	0.9	13
186	A Model of Corneal Graft Rejection in Semi-Inbred NIH Miniature Swine: Significant T-Cell Infiltration of Clinically Accepted Allografts. , 2012, 53, 3183.		13
187	Road to Fulfilment: Taming the Immune Response to Restore Vision. Ophthalmic Research, 2012, 48, 43-49.	1.0	13
188	Gene Therapy for Noninfectious Uveitis. Ocular Immunology and Inflammation, 2012, 20, 394-405.	1.0	13
189	Pleiotropic action of CpG-ODN on endothelium and macrophages attenuates angiogenesis through distinct pathways. Scientific Reports, 2016, 6, 31873.	1.6	13
190	Clinical spectrum of vitreoretinal lymphoma and its association with <i>MyD88</i> L265P mutation. Acta Ophthalmologica, 2019, 97, e138-e139.	0.6	13
191	Treatment of diabetic retinopathy through neuropeptide Yâ€mediated enhancement of neurovascular microenvironment. Journal of Cellular and Molecular Medicine, 2020, 24, 3958-3970.	1.6	13
192	Restoring retinal neurovascular health via substance P. Experimental Cell Research, 2019, 380, 115-123.	1.2	12
193	Genome-Wide Analysis in Swine Associates Corneal Graft Rejection with Donor-Recipient Mismatches in Three Novel Histocompatibility Regions and One Locus Homologous to the Mouse H-3 Locus. PLoS ONE, 2016, 11, e0152155.	1.1	12
194	Activation of C-reactive protein proinflammatory phenotype in the blood retinal barrier in vitro: implications for age-related macular degeneration. Aging, 2020, 12, 13905-13923.	1.4	12
195	Cytokines and immunopathogenesis of intraocular posterior segment inflammation. Ocular Immunology and Inflammation, 2003, 11, 17-28.	1.0	11
196	Ultrastructural evaluation of explanted opacified Hydroview (H60M) intraocular lenses. British Journal of Ophthalmology, 2007, 91, 243-247.	2.1	11
197	Activated adult microglia influence retinal progenitor cell proliferation and differentiation toward recoverin-expressing neuron-like cells in a co-culture model. Graefe's Archive for Clinical and Experimental Ophthalmology, 2015, 253, 1085-1096.	1.0	11
198	Imagingâ€Based Uveitis Surveillance in Juvenile Idiopathic Arthritis: Feasibility, Acceptability, and Diagnostic Performance. Arthritis and Rheumatology, 2021, 73, 330-335.	2.9	11

#	Article	IF	CITATIONS
199	Optical Coherence Tomography Angiography Findings in Dengue-Related Maculopathy: A Case Report. Ophthalmic Surgery Lasers and Imaging Retina, 2016, 47, 1057-1060.	0.4	11
200	Nasal administration of retinal antigens maintains immunosuppression of uveoretinitis in cyclosporin-a-treated lewis rats: Future treatment of endogenous posterior uveoretinitis?. Eye, 1997, 11, 445-452.	1.1	10
201	Cataract Surgery With Primary Intraocular Lens Implantation in Children With Chronic Uveitis. JAMA Ophthalmology, 2008, 126, 583.	2.6	10
202	Pars Plana Vitrectomy for Vitreoretinal Complications of Behçet Uveitis. European Journal of Ophthalmology, 2013, 23, 119-128.	0.7	10
203	Hypoxia inducible factors are dispensable for myeloid cell migration into the inflamed mouse eye. Scientific Reports, 2017, 7, 40830.	1.6	10
204	Alemtuzumab-induced remission of multiple sclerosis-associated uveitis. International Ophthalmology, 2017, 37, 1229-1233.	0.6	10
205	Re-programming immunosurveillance in persistent non-infectious ocular inflammation. Progress in Retinal and Eye Research, 2018, 65, 93-106.	7.3	10
206	Features of ectopic lymphoid-like structures in human uveitis. Experimental Eye Research, 2020, 191, 107901.	1.2	10
207	Mechanisms for inducing nasal mucosal tolerance in experimental autoimmune uveoretinitis. Methods, 2006, 38, 69-76.	1.9	9
208	Immune mechanisms of intraocular inflammation. Expert Review of Ophthalmology, 2010, 5, 43-58.	0.3	9
209	A novel pathogenic <scp>RBP</scp> â€3 peptide reveals epitope spreading in persistent experimental autoimmune uveoretinitis. Immunology, 2015, 146, 301-311.	2.0	9
210	Depot Indocyanine green dye for <i>in vivo</i> visualization of infiltrating leukocytes. DMM Disease Models and Mechanisms, 2015, 8, 1479-87.	1.2	9
211	Longâ€ŧerm outcome in patients with severe alcoholic hepatitis can be reliably determined using an in vitro measure of steroid sensitivity. Hepatology, 2015, 61, 1099-1099.	3.6	9
212	Intermediate uveitis associated with MS. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	9
213	Presumed CMV associated necrotizing retinopathyin a non-HIV immunocompromised host. Clinical and Experimental Ophthalmology, 2005, 33, 330-332.	1.3	8
214	The effect on visual function of Hydroview intraocular lens opacification: a cross-sectional study. Eye, 2010, 24, 1590-1598.	1.1	8
215	Intravenous immunoglobulin (IVIg) in the management of severe refractory vernal keratoconjunctivitis. British Journal of Ophthalmology, 2010, 94, 667-669.	2.1	8
216	Clinical outcomes of intravenous immunoglobulin therapy in refractory uveitis. International Ophthalmology, 2015, 35, 281-285.	0.6	8

#	Article	IF	CITATIONS
217	Soluble CD200 Correlates With Interleukin-6 Levels in Sera of COPD Patients: Potential Implication of the CD200/CD200R Axis in the Disease Course. Lung, 2017, 195, 59-68.	1.4	8
218	Augmenting Endogenous Levels of Retinal Annexin A1 Suppresses Uveitis in Mice. Translational Vision Science and Technology, 2017, 6, 10.	1.1	8
219	Corneal Transplant Follow-up Study II: a randomised trial to determine whether HLA class II matching reduces the risk of allograft rejection in penetrating keratoplasty. British Journal of Ophthalmology, 2020, , bjophthalmol-2020-317543.	2.1	8
220	Müller Cells Stabilize Microvasculature through Hypoxic Preconditioning. Cellular Physiology and Biochemistry, 2019, 52, 668-680.	1.1	8
221	The Cellular Composition of the Uveal Immune Environment. Frontiers in Medicine, 2021, 8, 721953.	1.2	8
222	Recent developments of neuroprotective agents for degenerative retinal disorders. Neural Regeneration Research, 2022, 17, 1919.	1.6	8
223	Retinal antigen-specific T cells mediate experimental autoimmune uveoretinitis (EAU) in PVG rat a model for tracking antigen-specific CD4+T cells in the inflamed eye. Ocular Immunology and Inflammation, 1995, 3, 261-270.	1.0	7
224	Single dose intranasal administration of retinal autoantigen generates a rapid accumulation and cell activation in draining lymph node and spleen: implications for tolerance therapy. British Journal of Ophthalmology, 2001, 85, 1001-1006.	2.1	7
225	Spatially Controlling Neuronal Adhesion and Inflammatory Reactions on Implantable Diamond. IEEE Journal on Emerging and Selected Topics in Circuits and Systems, 2011, 1, 557-565.	2.7	7
226	Perioperative socialization, care and monitoring of National Institutes of Health miniature swine undergoing ocular surgery and sampling of peripheral blood. Laboratory Animals, 2012, 46, 59-64.	0.5	7
227	Role of interleukin 33/ST2 axis in the immune-mediated pathogenesis of age-related macular degeneration. Lancet, The, 2015, 385, S97.	6.3	7
228	Corneal transplant follow-up study II (CTFS II): a prospective clinical trial to determine the influence of HLA class II matching on corneal transplant rejection: baseline donor and recipient characteristics. British Journal of Ophthalmology, 2019, 103, 132-136.	2.1	7
229	Understanding uveitis through the eyes of a horse: relevance of models of ocular inflammation to human disease. Ocular Immunology and Inflammation, 1998, 6, 211-214.	1.0	6
230	Lack of IFN-Î ³ Synthesis in Aqueous Humor during Corneal Graft Rejection Correlates with Suppressed Nitric Oxide Production by Macrophages. , 2008, 49, 4923.		6
231	The Role of Lipoprotein-Associated Phospholipase Aâ,, in a Murine Model of Experimental Autoimmune Uveoretinitis. PLoS ONE, 2015, 10, e0122093.	1.1	6
232	Phase IIb clinical trial of ranibizumab for the treatment of uveitic and idiopathic choroidal neovascular membranes. British Journal of Ophthalmology, 2016, 100, 1221-1226.	2.1	6
233	Management of paediatric ocular inflammatory disease in the UK: national survey of practice. Eye, 2020, 34, 591-592.	1.1	6
234	Intravenous indocyanine green dye is insufficient for robust immune cell labelling in the human retina. PLoS ONE, 2020, 15, e0226311.	1.1	6

#	Article	IF	CITATIONS
235	Interleukin-33 regulates metabolic reprogramming of the retinal pigment epithelium in response to immune stressors. JCI Insight, 2021, 6, .	2.3	6
236	Applications of three-dimensional printing in ophthalmology. Survey of Ophthalmology, 2022, 67, 1287-1310.	1.7	6
237	Quantitative and qualitative assessment of anterior segment optical coherence tomography capture of disease state in childhood anterior uveitis. British Journal of Ophthalmology, 2023, 107, 966-972.	2.1	6
238	The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs. Rheumatology, 2022, 61, e255-e266.	0.9	6
239	Induction or suppression of a B cell-specific response to self antigenin vivo is dependent upon dendritic cell activation via the TNF-α receptor at the time of antigen uptake. European Journal of Immunology, 2000, 30, 2268-2280.	1.6	5
240	Factors affecting rejection of second corneal transplants in rats1. Transplantation, 2004, 77, 492-496.	0.5	5
241	Mapping Immune Responses to mRBP-3 1-16 Peptide with Altered Peptide Ligands. , 2006, 47, 2027.		5
242	Effects of triamcinolone acetonide injections with and without preservative. British Journal of Ophthalmology, 2007, 91, 1099-1101.	2.1	5
243	Treatment with interleukinâ€33 is nonâ€toxic and protects retinal pigment epithelium in an ageing model of outer retinal degeneration. Journal of Cellular and Molecular Medicine, 2020, 24, 13546-13550.	1.6	5
244	Quantitative Assessment of Experimental Ocular Inflammatory Disease. Frontiers in Immunology, 2021, 12, 630022.	2.2	5
245	Unravelling the therapeutic potential of IL-33 for atrophic AMD. Eye, 2022, 36, 266-272.	1.1	5
246	The Bromodomain and Extra-Terminal Protein Inhibitor OTX015 Suppresses T Helper Cell Proliferation and Differentiation. Current Molecular Medicine, 2019, 18, 594-601.	0.6	5
247	The use of lithium clearance studies in theearly detection of cyclosporin a (CsA) nephrotoxicity: a protocol of renal function assessment with CsA therapy. Current Eye Research, 1992, 11, 215-218.	0.7	4
248	Shared care approach to managing ophthalmological disease in patients with positive treponemal serology: a case series. International Journal of STD and AIDS, 2012, 23, 291-296.	0.5	4
249	Diagnostic techniques for inflammatory eye disease: past, present and future: a review. BMC Ophthalmology, 2013, 13, 41.	0.6	4
250	Blinded by lack of evidence. Rheumatology, 2013, 52, 765-766.	0.9	4
251	Treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope. Rheumatology, 2021, 60, 1588-1592.	0.9	4
252	Peptide-based immunotherapy against oxidized elastin ameliorates pathology in mouse model of smoke-induced ocular injury. Experimental Eye Research, 2021, 212, 108755.	1.2	4

#	Article	IF	CITATIONS
253	Are we still reluctant to immunosuppress?. Clinical and Experimental Ophthalmology, 2005, 33, 1-2.	1.3	3
254	PLASMAPHERESIS IN THE MANAGEMENT OF CHOROIDAL VASCULITIS ASSOCIATED WITH C-ANCA POSITIVE RENAL VASCULITIS. Retinal Cases and Brief Reports, 2010, 4, 356-360.	0.3	3
255	Functional Analysis of Retinal Microglia and Their Effects on Progenitors. Methods in Molecular Biology, 2012, 935, 271-283.	0.4	3
256	Local targeting of the CD200-CD200R axis does not promote corneal graft survival. Experimental Eye Research, 2015, 130, 1-8.	1.2	3
257	Bevacizumab for treatment of choroidal neovascularization secondary to candida chorioretinitis. International Ophthalmology, 2018, 38, 781-785.	0.6	3
258	Tumor Necrosis Factor Alpha-Targeted Therapies in Uveitis. , 2007, , 177-192.		3
259	UNICORNS: Uveitis in childhood prospective national cohort study protocol. F1000Research, 0, 9, 1196.	0.8	3
260	Development of a Nationally Agreed Core Clinical Dataset for Childhood Onset Uveitis. Frontiers in Pediatrics, 0, 10, .	0.9	3
261	Matrix bound SFD mutant TIMP-3 is more stable than wild type TIMP-3. British Journal of Ophthalmology, 2007, 91, 1073-1076.	2.1	2
262	Diamonds are forever!. Eye, 2009, 23, 1228-1228.	1.1	1
263	Patient, surgical, and lens-related factors, and their association with Hydroview intraocular lens opacification. Eye, 2010, 24, 1627-1628.	1.1	1
264	Lens Implant Opacification. Ophthalmology, 2011, 118, 2095-2096.	2.5	1
265	Enhancing Inflammation as an Adjuvant to Neovascular AMD Therapy. , 2015, 56, 5431.		1
266	Achieving Quiescence with Fluocinolone Implants. Case Reports in Ophthalmology, 2021, 12, 356-362.	0.3	1
267	Adalimumab in the treatment of pediatric patients with chronic noninfectious anterior uveitis. Expert Review of Ophthalmology, 2021, 16, 231-241.	0.3	1
268	Steroid Sensitivity in Uveitis. Essentials in Ophthalmology, 2009, , 45-54.	0.0	1
269	Mycophenolate mofetil therapy. Ophthalmology, 1999, 106, 1645.	2.5	0
270	Responding to readers' and authors' needs. British Journal of Ophthalmology, 2003, 87, 808-808.	2.1	0

#	Article	IF	CITATIONS
271	Online first in the British Journal of Ophthalmology. British Journal of Ophthalmology, 2006, 90, 260-260.	2.1	0
272	Reply to Amissah-Arthur et al. Eye, 2010, 24, 1116-1116.	1.1	0
273	Response to Dr Agrawal. Eye, 2012, 26, 890-891.	1.1	Ο
274	Assessing the painful, uninflamed eye in primary care. BMJ, The, 2015, 351, h3216.	3.0	0
275	Reply. Ophthalmology, 2018, 125, e54.	2.5	Ο
276	Reply. Ophthalmology, 2019, 126, e24-e25.	2.5	0
277	Nitric Oxide in Experimental Autoimmune Uveoretinitis. , 2008, , 107-119.		Ο
278	TNF Activation and Nitric Oxide Production in EAU. , 2008, , 121-129.		0
279	Immunology of Uveitis. , 2016, , 39-81.		Ο
280	Therapeutic Vitrectomy for Noninfectious Uveitis. , 2008, , 35-45.		0
281	Title is missing!. , 2020, 15, e0226311.		Ο
282	Title is missing!. , 2020, 15, e0226311.		0
283	Title is missing!. , 2020, 15, e0226311.		0
284	Title is missing!. , 2020, 15, e0226311.		0
285	Ocular Toxoplasmosis Associated Dark Without Pressure. Ocular Immunology and Inflammation, 2022, , 1-3.	1.0	Ο